Last reviewed · How we verify

Gelatin Sponge Sheet

Tianjin Medical University Eye Hospital · FDA-approved active Small molecule Quality 5/100

The Gelatin Sponge Sheet, marketed by Tianjin Medical University Eye Hospital, is a unique product in the ophthalmic surgical market. Its key strength lies in the key composition patent, which is set to expire in 2028, providing a period of exclusive market protection. The primary risk is the potential increase in competition following the patent expiry, which could erode market share and revenue.

At a glance

Generic nameGelatin Sponge Sheet
Also known asgel foam
SponsorTianjin Medical University Eye Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: